Home・Список акций・Gossamer Bio Inc

Gossamer Bio Inc

Открыт

СекторЗдравоохранение

0.18 5.88

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.17

Макс.

0.18

Ключевые показатели
By Trading Economics
Доход	574K -47M
Продажи	3.2M 17M
Прибыль на акцию	-0.2
Рентабельность продаж	-275.223
Сотрудники	161
EBITDA	2.1M -44M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+494.44% upside

Дивиденды
By Acuity
Следующий отчет о доходах	10 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	5.4M 85M
Предыдущая цена открытия	-5.7
Предыдущая цена закрытия	0.18

Новостные настроения

By Acuity

63%

37%

296 / 340 Рейтинг в Healthcare

Gossamer Bio Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

3 авг. 2026 г., 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 авг. 2026 г., 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 июл. 2026 г., 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 июл. 2026 г., 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 июл. 2026 г., 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 июл. 2026 г., 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 июл. 2026 г., 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 июл. 2026 г., 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 июл. 2026 г., 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 июл. 2026 г., 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 июл. 2026 г., 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 июл. 2026 г., 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Сравнение c конкурентами

Изменение цены

Gossamer Bio Inc Прогноз

Целевая цена

By TipRanks

494.44% рост

Прогноз на 12 месяцев

Средняя 1.07 USD 494.44%

Максимум 2 USD

Минимум 0.28 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Gossamer Bio Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

5 ratings

Покупка

Удержание

Продажа

Основано на мнении 5 аналитиков, присваивавших рейтинги акциям Gossamer Bio Inc – Данные за последние 3 месяца.

Настроения

By Acuity

296 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.